1. |
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD, 2017, http://www.goldCOPD.org.
|
2. |
Vestbo J, Hurd SS, Agustí AG,et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med, 2013, 187(4): 347-365.
|
3. |
Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol, 2011, 52(1): 21-27.
|
4. |
Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med, 2012, 12:26.
|
5. |
Graat-Verboom L, Wouters EF, Smeenk FW, et al.Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J, 2009, 34(1): 209-218.
|
6. |
Papaioannou A, Watts NB, Kendler DL,et al. Diagnosis and management of vertebral fractures in elderly adults. Am J Med, 2002, 113(3): 220-228.
|
7. |
Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res, 1992, 7(2): 221-227.
|
8. |
Majumdar SR, Villa-Roel C, Lyons KJ, et al.Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med, 2010, 104(2): 260-6.
|
9. |
Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med, 1996, 101(3): 262-269.
|
10. |
Watanabe R, Tanaka T, Aita K, et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab, 2015, 33(4): 392-400.
|
11. |
Regan EA, Jaramillo J. It’s the fracture that matters -bone disease in COPD patients. COPD, 2012, 9(4): 319-321.
|
12. |
Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest, 2011, 139(3): 648-657.
|
13. |
Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res, 2011, 26(3): 561-568.
|
14. |
Romme EA, Smeenk FW, Rutten EP, et al. Osteoporosis in chronic obstructive pulmonary disease. Expert Rev Respir Med, 2013, 7(4): 397-410.
|
15. |
Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford), 2009, 48(suppl 4): iv3-8.
|
16. |
Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol, 2008, 19(5): 444-451.
|
17. |
Steiner NK, Milhorn D, Hammett-Stabler C. Osteoporosis in men. Clin Biochem, 2014, 47(10-11): 950-959.
|
18. |
Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res, 2011, 12:157.
|
19. |
Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort study. Eur Respir J, 2010, 35(3): 540-548.
|
20. |
Bolton CE, Stone MD, Edwards PH, et al. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis, 2009, 6(2): 81-87.
|
21. |
Zhang PF, Pan L, Luo ZY, et al. Interrelationship of circulating matrix metalloproteinase-9, TNF-α and OPG/RANK/RANKL systems in COPD patients with osteoporosis. COPD, 2013, 10(6): 650-6.
|
22. |
Pauwels RA, Buist AS, Ma P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care, 2001, 46(8): 798-825.
|
23. |
Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int, 2001, 68(5): 259-270.
|
24. |
Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int, 2012, 23:2081-2092.
|
25. |
邢爱民. 慢性阻塞性肺疾病合并骨质疏松症的相关研究进展. 山东医药, 2014, 54(15): 98-100.
|
26. |
蔡柏蔷, 李龙芸. 协和呼吸病学. 沈阳: 中国协和医科大学出版社, 2011, 1078-1080.
|
27. |
曹锡文, 陈鹏, 郭志文, 等. c-fos 在吸烟刺激骨吸收中的作用. 湘南学院学报, 2010, 12(4): 1-4.
|
28. |
Førli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med, 2004, 256:56-62.
|
29. |
Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med, 2013, 45:91-96.
|
30. |
Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev, 2001, 22(4): 477-501.
|
31. |
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004, 19(6): 893-9.
|
32. |
Suda T, Takahashi N, Udagawa N, et al. MartinTJModulation of osteoclast differentiation and function by the newmembers of the tumor necrosis factor receptor and ligand families. Endocr Rev, 1999, 20:345-357.
|
33. |
Dimai HP, Domej W, Leb G,et al. Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res. 2001 Nov;16(11):2132-41.
|
34. |
MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med, 2013, 45(3): 291-300.
|
35. |
Garcia-Rio F, Miravitlles M, Soriano JB, et al.EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease:a population-based study. Respir Res, 2010, 11:63.
|
36. |
Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7): 574-580.
|
37. |
Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine, 2012, 42(1): 190-195.
|